[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655897":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":25,"interventions":44,"overallOfficials":58,"centralContacts":62,"locations":71,"responsibleParty":88,"collaborators":13,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":13,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":13,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":120,"whyStopped":13,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Huazhong University of Science and Technology","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Change in Lean Body Mass From Baseline to Week 12","Lean body mass will be measured using dual-energy X-ray absorptiometry (DXA). The primary outcome is the change in whole-body lean body mass, expressed in kilograms (kg), from baseline to week 12. A higher or lower change indicates the degree of preservation or loss of lean body mass during GLP-1RA treatment.","Baseline and Week 12",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":19,"maskingDescription":13,"whoMasked":20},"QUADRUPLE",[21,22,23,24],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[26,31,36,40],{"label":27,"type":28,"description":13,"interventionNames":29},"Yeast Protein Group","EXPERIMENTAL",[30],"Dietary Supplement: Yeast Protein",{"label":32,"type":33,"description":13,"interventionNames":34},"Whey Protein Group","ACTIVE_COMPARATOR",[35],"Dietary Supplement: Whey Protein",{"label":37,"type":28,"description":13,"interventionNames":38},"Yeast Protein\u002FWhey Protein Blend Group",[39],"Dietary Supplement: Yeast Protein\u002FWhey Protein Blend (1:1)",{"label":41,"type":42,"description":43,"interventionNames":13},"Blank Control Group","NO_INTERVENTION","Participants receive no study protein product and continue their usual diet and clinically prescribed GLP-1RA treatment.",[45,50,54],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":13},"DIETARY_SUPPLEMENT","Yeast Protein","Participants will consume approximately 20 g of the yeast protein study product once daily for 12 weeks. The product is provided as a powder and is reconstituted with approximately 150-200 mL of warm water before consumption. The product contains yeast protein as the principal protein source.",[27],{"type":46,"name":51,"description":52,"armGroupLabels":53,"otherNames":13},"Whey Protein","Participants will consume approximately 20 g of the whey protein study product once daily for 12 weeks. The product is provided as a powder and is reconstituted with approximately 150-200 mL of warm water before consumption. The product contains whey protein as the principal protein source.",[32],{"type":46,"name":55,"description":56,"armGroupLabels":57,"otherNames":13},"Yeast Protein\u002FWhey Protein Blend (1:1)","Participants will consume approximately 20 g of the yeast protein\u002Fwhey protein blend study product once daily for 12 weeks. The product is provided as a powder and is reconstituted with approximately 150-200 mL of warm water before consumption. The protein blend contains yeast protein and whey protein in a 1:1 ratio by weight.",[37],[59],{"name":60,"affiliation":5,"role":61},"Liegang Liu, PhD","PRINCIPAL_INVESTIGATOR",[63,68],{"name":64,"role":65,"phone":66,"phoneExt":13,"email":67},"Shufang Xu, MD","CONTACT","18802775169","358228927@qq.com",{"name":69,"role":65,"phone":13,"phoneExt":13,"email":70},"Qi Song, Master","M202575871@hust.edu.cn",[72],{"facility":73,"status":13,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"Shenzhen Qianhai Taikang Hospital","Shenzhen","Guangdong","518000","China","CN",{"type":80,"coordinates":81},"Point",[82,83],114.0683,22.54554,{"lat":83,"lon":82},[86,87],{"name":64,"role":65,"phone":66,"phoneExt":13,"email":67},{"name":69,"role":65,"phone":13,"phoneExt":13,"email":70},{"type":61,"investigatorFullName":89,"investigatorTitle":90,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Liegang Liu","Professor","100655897","yeast-protein-supplementation-and-muscle-preservation-during-glp-1ra-induced-weight-loss-100655897",false,"NCT07817823","Yeast Protein Supplementation and Muscle Preservation During GLP-1RA-Induced Weight Loss","Evaluation of the Intervention Effect of Yeast Protein Supplementation on Muscle Loss in Individuals Undergoing Weight Loss With Glucagon-Like Peptide-1 Receptor Agonists","Inclusion Criteria:\n\n* Adults aged 25-50 years with overweight or obesity, defined as BMI ≥24.0 kg\u002Fm², who meet the clinical indication for GLP-1RA-related weight-loss treatment.\n\nPlanning to initiate GLP-1RA treatment, or having initiated GLP-1RA treatment within the previous 4 weeks, and intending to continue treatment for at least 12 weeks.\n\nAble and willing to provide written informed consent and comply with the 12-week intervention, follow-up visits, dietary assessments, body composition measurements, muscle function tests, and biological sample collection.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to yeast protein, whey protein, milk-derived ingredients, or other components of the study products.\n\nUnable to undergo dual-energy X-ray absorptiometry (DXA) or having a contraindication to DXA examination.\n\nSarcopenia at baseline, defined by appendicular skeletal muscle mass index (ASMI) \\\u003C7.0 kg\u002Fm² in men or \\\u003C5.4 kg\u002Fm² in women.\n\nSevere cardiovascular or cerebrovascular disease, hepatic or renal insufficiency, malignancy, or other diseases that may substantially affect skeletal muscle metabolism.\n\nRegular use of protein powder or additional protein supplementation equivalent to ≥0.3 g\u002Fkg body weight per day.\n\nInitiation or dose adjustment of statins within the previous 3 months, or a history of statin-associated myopathy.\n\nCurrent participation in another weight-loss program or clinical intervention trial.\n\nLong-term use of systemic glucocorticoids, anabolic agents, or other medications that may substantially affect protein or skeletal muscle metabolism.\n\nUse of other weight-loss medications, fat-loss supplements, or muscle-enhancing products within the previous 3 months, apart from the prespecified GLP-1RA-related treatment.\n\nUse of antibiotics, probiotics, prebiotics, or other products or medications likely to substantially affect the gut microbiota within the previous 1 month.","ALL","25 Years","50 Years",{"count":102,"type":103},200,"ESTIMATED","INTERVENTIONAL",[106],"NA","The goal of this clinical trial is to evaluate whether yeast protein supplementation can help preserve lean body mass and muscle function in adults with overweight or obesity receiving GLP-1 receptor agonist-related treatment for weight loss. The main questions it aims to answer are: 1. Does yeast protein supplementation reduce the loss of lean body mass during GLP-1RA-related weight loss? 2. Does yeast protein supplementation improve or preserve muscle function? 3. Does yeast protein supplementation affect metabolic status, inflammation, gut barrier function, gut microbiota, and related metabolites?\n\nResearchers will compare yeast protein with whey protein and a yeast protein\u002Fwhey protein blend to evaluate the effects of different protein sources on muscle-related outcomes during GLP-1RA treatment.\n\nParticipants will: 1. Take the assigned study product every day for 12 weeks, approximately 20 g per day. 2. Return used study-product sachets every 4 weeks so that adherence can be assessed and the next supply can be provided. 3. Attend study visits at baseline, week 4, and week 12 for questionnaire surveys, physical measurements, body composition assessment by DXA, muscle function tests, dietary assessment, and blood sampling. 4. Complete a simplified follow-up at week 8 to record GLP-1RA use and dose changes, study-product adherence, adverse events, and major changes in diet or physical activity. 5. Complete sleep assessment using a wearable sleep-monitoring device and the Pittsburgh Sleep Quality Index at baseline and week 12. 6. Provide stool samples at baseline and week 12 for assessment of gut microbiota and related metabolites.",[109],"Overweight and Obesity in Adults Receiving GLP-1RA Treatment",[111,112,113,114,115,116,117,118,119],"GLP-1 receptor agonist","Overweight","Obesity","Yeast protein","Whey protein","Lean body mass","Muscle function","Body composition","Gut microbiota","NOT_YET_RECRUITING","2026-09-09",{"date":123,"type":124},"2026-09-14","ACTUAL",{"date":126,"type":103},"2026-09-20",{"date":128,"type":103},"2027-05-30",{"name":5,"class":6},1]